Equities analysts expect that Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) (TSE:AUP) will post ($0.35) earnings per share for the current quarter, Zacks reports. Five analysts have made estimates for Aurinia Pharmaceuticals’ earnings, with the highest EPS estimate coming in at ($0.30) and the lowest estimate coming in at ($0.37). Aurinia Pharmaceuticals reported earnings per share of ($0.26) in the same quarter last year, which suggests a negative year-over-year growth rate of 34.6%. The business is expected to issue its next quarterly earnings report on Tuesday, August 10th.
According to Zacks, analysts expect that Aurinia Pharmaceuticals will report full year earnings of ($1.22) per share for the current fiscal year, with EPS estimates ranging from ($1.46) to ($1.02). For the next year, analysts anticipate that the company will report earnings of ($0.36) per share, with EPS estimates ranging from ($0.85) to ($0.02). Zacks’ earnings per share calculations are a mean average based on a survey of sell-side research firms that that provide coverage for Aurinia Pharmaceuticals.
Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last posted its quarterly earnings data on Wednesday, May 5th. The biotechnology company reported ($0.40) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.35) by ($0.05). The business had revenue of $0.91 million during the quarter, compared to the consensus estimate of $2.30 million. Aurinia Pharmaceuticals had a negative return on equity of 34.48% and a negative net margin of 239.29%.
NASDAQ AUPH traded up $0.49 during trading hours on Thursday, hitting $14.44. 171,510 shares of the company’s stock were exchanged, compared to its average volume of 4,189,355. The stock has a market cap of $1.85 billion, a price-to-earnings ratio of -14.09 and a beta of 0.58. The firm has a 50-day moving average of $12.66. Aurinia Pharmaceuticals has a 1-year low of $9.72 and a 1-year high of $20.50.
In related news, CEO Peter Greenleaf acquired 5,125 shares of the stock in a transaction dated Tuesday, May 11th. The stock was purchased at an average cost of $10.71 per share, with a total value of $54,888.75. Following the completion of the purchase, the chief executive officer now directly owns 10,461 shares in the company, valued at approximately $112,037.31. The purchase was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Jill Leversage bought 2,500 shares of the company’s stock in a transaction dated Tuesday, May 11th. The stock was bought at an average price of $10.96 per share, for a total transaction of $27,400.00. Following the acquisition, the director now directly owns 3,700 shares of the company’s stock, valued at $40,552. The disclosure for this purchase can be found here. In the last ninety days, insiders purchased 18,525 shares of company stock worth $191,722. 3.10% of the stock is owned by insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Valeo Financial Advisors LLC bought a new position in shares of Aurinia Pharmaceuticals during the first quarter valued at about $29,000. Sowell Financial Services LLC increased its stake in Aurinia Pharmaceuticals by 72.6% in the 1st quarter. Sowell Financial Services LLC now owns 2,512 shares of the biotechnology company’s stock valued at $31,000 after buying an additional 1,057 shares during the last quarter. Private Capital Group LLC bought a new position in shares of Aurinia Pharmaceuticals during the 1st quarter worth approximately $34,000. Northern Oak Wealth Management Inc. purchased a new position in shares of Aurinia Pharmaceuticals in the 1st quarter worth approximately $39,000. Finally, Penserra Capital Management LLC grew its holdings in shares of Aurinia Pharmaceuticals by 172.2% in the fourth quarter. Penserra Capital Management LLC now owns 2,940 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 1,860 shares in the last quarter. Hedge funds and other institutional investors own 40.79% of the company’s stock.
About Aurinia Pharmaceuticals
Aurinia Pharmaceuticals Inc, a biopharmaceutical company, develops and commercializes therapies to treat various diseases with unmet medical need in Japan and China. The company offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co, Ltd.
Featured Article: Sell-Side Analysts
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aurinia Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.